Emerging markets are of significant importance to biotech and pharmaceutical companies for their drug development programs.
Increasing costs and patient recruitment difficulties continue to challenge trials in North America and Europe. Emerging markets are becoming viable options, due to the very large and treatment-naïve patient populations, access to patients and their generally lower medical costs.
PRA has the local and regulatory knowledge, investigator relationships, expertise and experience to help you run a successful trial in a variety of emerging markets.
Click the links below to learn more about how we can help you with your clinical trial in these emerging markets.
